The Effect of Polymorphisms of Beta2 Adrenoceptors on Response to Long-acting Beta2 Agonists in Iranian Asthmatic Patients
Abstract
The results of many studies suggested possible relationship between polymorphism at codons 16 and 27 and development of tolerance to beta-2 adrenoceptor agonist responses as well as disease severity in asthmatic patients. This study was designed to evaluate the effect of polymorphism of beta2 adrenoceptors on response to salmeterol and fluticasone (as inhaled Seretide).
Sixty-four patients with either mild or moderate-severe asthma were evaluated in this study. A four-week therapy with Seretide was conducted in moderate-severe asthmatics. The respiratory parameters and asthma score (based on GINA guidelines) were measured before and after run in period. Blood samples were genotyped at codons 16 and 27.
No significant difference was observed in genotypes neither at codon 16 nor at codon 27 between mild and moderate-severe asthma groups. However, Patients in Arg/Arg (n = 8) category showed significant improvement in asthma control parameters and lung function compared with Arg/Gly genotype (n =20).
These results suggest that genotyping may be useful in some asthmatic patients in order to better tailor asthma treatment plan.
1. Self TH, Chrisman CR, Finch CK. Asthma. In: Koda- Kimble MA, Young LY, Alldredge BK, Corelli RL, Guglielmo BJ, Kradjan WA, Williams BR, editors. Applied Therapeutics: The Clinical Use Of Drugs, 9th Edition. USA: Lippincott Williams & Wilkins, 2009.
2. Stauffer J. Disorders of the airways. In: Tierney LM, McPhee SJ, Pafadakis MA, editors Current Medical Diagnosis and Treatment. Appleton and Lange, 1997:
241–260.3. Liggett SB. Update on current concepts of the molecular basis of [beta] 2-adrenergic receptor signaling. J Allergy Clin Immunol 2002; 110(6Suppl):S223-7.
4. Liggett SB. The pharmacogenetics of [beta] 2-adrenergic receptors: Relevance to asthma. J Allergy Clin Immunol 2000; 105(2 Pt 2):S487-S92.
5. Reihsaus E, Innis M, MacIntyre N, Liggett S. Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol 1993; 8(3):334-9.
6. Green S, Turki J, Bejarano P, Hall I, Liggett S. Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am J Respir Cell Mol Biol 1995; 13(1):25-33.
7. Drysdale C, McGraw D, Stack C, Stephens J, Judson R, Nandabalan K, et al. Complex promoter and coding region 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci U S A 2000; 97(19):10483-8.
8. Israel E, Drazen J, Liggett S, Boushey H, Cherniack R, Chinchilli V, et al. The effect of polymorphisms of the beta 2-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 2000;162(1):75-80.
9. Taylor D, Drazen J, Herbison G, Yandava C, Hancox R, Town G. Asthma exacerbations during long term agonist use: influence of 2 adrenoceptor polymorphism. Thorax 2000; 55(9):762-7.
10. Joos L, Paré P, Sandford A. [beta] 2-Adrenergic receptor polymorphisms and asthma. Curr Opin Pulm Med 2001;7(2):69-74.
11. Hancox R, Sears M, Taylor D. Polymorphism of the beta2-adrenoceptor and the response to long-term beta2- agonist therapy in asthma. Eur Respir J 1998; 11(3):589-93.
12. Bateman E, Hurd S, Barnes P, Bousquet J, Drazen J, FitzGerald M, Gibson P, Ohta K, O'Byrne P, Pedersen S, Pizzichini E, Sullivan S, Wenzel S, Zar H. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008; 31(1):143-178.
13. Banks H. National asthma education and prevention program. Expert panel report 3: guidelines for the diagnosis and management of asthma updated on selected topics2007.
14. Sambrook J, Russell D. Molecular cloning: a laboratory manual, USA: Cold Spring Harbor, 2001: 6.4-6.58.
15. Martinez F, Graves P, Baldini M, Solomon S, Erickson R.Association between genetic polymorphisms of the beta2- adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 1997;100(12):3184-8.
16. Weir T, Mallek N, Sandford A, Bai T, Awadh N, Fitzgerald J, et al. beta 2-Adrenergic receptor haplotypes in mild, moderate and fatal/near fatal asthma. Am J Respir Crit Care Med 1998; 158(3):787-91.
17. Holloway J, Dunbar P, Riley G, Sawyer G, Fitzharris P, Pearce N, et al. Association of 2 adrenergic receptor polymorphisms with severe asthma. Clin Exp Allergy 2000; 30(8):1097-103.
18. Wechsler M, Lehman E, Lazarus S, Lemanske Jr R, Boushey H, Deykin A, et al. Beta-adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med 2006; 173(5):519.
19. Green S, Cole G, Jacinto M, Innis M, Liggett S. A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem 1993; 268(31):23116-21.
20. Lee D, Currie G, Hall I, Lima J, Lipworth B. The arginine-16 beta2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol. Br J Clin Pharmacol 2004; 57(1):68-75.
21. Shore S, Drazen J. Beta-agonists and asthma: too much of a good thing? J Clin Invest 2003; 112(4):495-7.
22. McGraw D, Almoosa K, Paul R, Kobilka B, Liggett S.Antithetic regulation by -adrenergic receptors of G q receptor signaling via phospholipase C underlies the airway -agonist paradox. J Clin Invest 2003;112(4):619-26.
23. Bleecker E, Postma D, Lawrance R, Meyers D, Ambrose H, Goldman M. Effect of ADRB2 polymorphisms on response to longacting [beta] 2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 2008; 370(9605):2118-25.
24. Bleecker E, Yancey S, Baitinger L, Edwards L, Klotsman M, Anderson W, et al. Salmeterol response is not affected by [beta] 2-adrenergic receptor genotype in subjects with persistent asthma. J Allergy Clin Immunol 2006;118(4):809-16.
25. Haselkorn T, Lee J, Mink D. Racial disparities in asthma- related health outcomes in severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 2008; 101(3):256-63.
26. Choudhry S, Ung N, Avila P, Ziv E, Nazario S, Casal J, et al. Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma. Am J Respir Crit Care med 2005; 171(6):563-70.
27. Wechsler M, Kunselman S, Chinchilli V, Bleecker E, Boushey H, Calhoun W, et al. Effect of [beta] 2- adrenergic receptor polymorphism on response to longacting [beta] 2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial. Lancet 2009; 374(9703):1754-64.
28. Mak J, Nishikawa M, Barnes P. Glucocorticosteroids increase beta 2-adrenergic receptor transcription in human lung. Am J Physiol 1995; 268 (1 Pt 1):L41-6.
29. Mak J, Nishikawa M, Shirasaki H, Miyayasu K, Barnes P. Protective effects of a glucocorticoid on downregulation of pulmonary beta 2-adrenergic receptors in vivo. J Clin Invest 1995; 96(1):99-106.
30. Chong L, Drury D, Dummer J, Ghahramani P, Schleimer R, Peachell P. Protection by dexamethasone of the functional desensitization to 2 adrenoceptor mediated responses in human lung mast cells. Br J Pharmacol 1 997; 121(4):717-22.
Files | ||
Issue | Vol 12, No 4 (2013) | |
Section | Articles | |
Keywords | ||
Asthma Beta-adrenoceptor Polymorphism |
Rights and permissions | |
![]() |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |